[go: up one dir, main page]

SMT201600311B - Inibitori di cdk - Google Patents

Inibitori di cdk

Info

Publication number
SMT201600311B
SMT201600311B SM201600311T SM201600311T SMT201600311B SM T201600311 B SMT201600311 B SM T201600311B SM 201600311 T SM201600311 T SM 201600311T SM 201600311 T SM201600311 T SM 201600311T SM T201600311 B SMT201600311 B SM T201600311B
Authority
SM
San Marino
Prior art keywords
cdk inhibitors
cdk
inhibitors
Prior art date
Application number
SM201600311T
Other languages
English (en)
Inventor
Francis X Tavares
Jay C Strum
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600311(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of SMT201600311B publication Critical patent/SMT201600311B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM201600311T 2010-10-25 2016-09-09 Inibitori di cdk SMT201600311B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40649810P 2010-10-25 2010-10-25
PCT/US2011/057749 WO2012061156A1 (en) 2010-10-25 2011-10-25 Cdk inhibitors

Publications (1)

Publication Number Publication Date
SMT201600311B true SMT201600311B (it) 2016-11-10

Family

ID=46024778

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600311T SMT201600311B (it) 2010-10-25 2016-09-09 Inibitori di cdk

Country Status (25)

Country Link
US (2) US8598197B2 (it)
EP (6) EP2955183A1 (it)
JP (4) JP5923509B2 (it)
KR (4) KR20200137048A (it)
CN (5) CN106967074A (it)
AU (5) AU2011323739B2 (it)
BR (1) BR112013010018B1 (it)
CA (2) CA2961937C (it)
CY (1) CY1118004T1 (it)
DK (1) DK2632467T3 (it)
ES (1) ES2592515T3 (it)
HK (2) HK1197067A1 (it)
HR (1) HRP20161092T1 (it)
HU (1) HUE030714T2 (it)
IL (5) IL225940A0 (it)
LT (1) LT2632467T (it)
MX (4) MX385616B (it)
PL (1) PL2632467T3 (it)
PT (1) PT2632467T (it)
RS (1) RS55135B1 (it)
RU (1) RU2621674C2 (it)
SG (2) SG10201508715YA (it)
SI (1) SI2632467T1 (it)
SM (1) SMT201600311B (it)
WO (1) WO2012061156A1 (it)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
SMT201800206T1 (it) 2008-07-08 2018-05-02 Incyte Holdings Corp 1,2,5-ossadiazoli come inibitori di indoleamina 2,3-diossigenasi
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP2640394A4 (en) 2010-11-17 2015-02-25 Univ North Carolina PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
US10202392B2 (en) * 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
WO2014144740A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
CN108434149B (zh) 2013-03-15 2021-05-28 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
WO2014144596A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
AU2017290362B2 (en) 2016-07-01 2021-08-05 Pharmacosmos Holding A/S Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
BR112018077136A2 (pt) * 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
RU2769251C2 (ru) 2016-08-23 2022-03-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Комбинированная терапия для лечения гепатоцеллюлярной карциномы
ES2934846T3 (es) 2016-10-20 2023-02-27 Pfizer Inhibidores de CDK para tratamiento de PAH
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
CN108699067B (zh) * 2016-11-11 2021-06-15 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
JP2019536805A (ja) 2016-12-05 2019-12-19 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法計画中の免疫応答の保護
IL267795B2 (en) 2017-01-06 2023-02-01 G1 Therapeutics Inc Combination therapy for the treatment of cancer
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2018156812A1 (en) 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects
WO2018170447A1 (en) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EA201992768A1 (ru) 2017-06-29 2020-05-19 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
BR112020013915A2 (pt) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020097625A1 (en) * 2018-11-09 2020-05-14 G1 Therapeutics, Inc. Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN111377924A (zh) * 2018-12-29 2020-07-07 武汉光谷通用名药物研究院有限公司 新型cdk4抑制剂及其用途
CN111377935B (zh) * 2018-12-29 2021-06-29 武汉光谷通用名药物研究院有限公司 选择性cdk4/6抑制剂及其应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CA3130210A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
TW202114684A (zh) 2019-06-18 2021-04-16 美商G1治療公司 增強癌症病患之抗腫瘤免疫之方法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ｉｄｏ阻害剤の投与レジメン
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN121270549A (zh) 2020-04-16 2026-01-06 因赛特公司 稠合三环kras抑制剂
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
EP4153597B1 (en) 2020-05-19 2025-09-10 Pharmacosmos Holding A/S Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
CN115698015A (zh) * 2020-06-11 2023-02-03 卢内拉生物技术有限公司 选择性cdk4/6抑制剂癌症治疗
WO2021257587A1 (en) 2020-06-15 2021-12-23 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP4225758B1 (en) * 2020-10-08 2025-11-26 Assia Chemical Industries Ltd. Solid state forms of trilaciclib and of trilaciclib salts
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL309642A (en) 2021-07-07 2024-02-01 Incyte Corp Tricyclic compounds as inhibitors of Kras
US20230114765A1 (en) 2021-07-14 2023-04-13 Incyte Corporation Tricyclic compounds as inhibitors of kras
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
US20230226040A1 (en) 2021-11-22 2023-07-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3244187A1 (en) 2021-12-22 2023-06-29 Incyte Corporation SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND THEIR METHODS OF PREPARATION
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
EP4486458A1 (en) 2022-02-28 2025-01-08 Teva Pharmaceuticals International GmbH Crystalline forms of trilaciclib and trilaciclib salts
IL315457A (en) 2022-03-07 2024-11-01 Incyte Corp Solid forms, salts and preparation processes of the Sidikii2 inhibitor
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN115536663A (zh) * 2022-10-11 2022-12-30 杭州科巢生物科技有限公司 一种曲拉西利中间体及其制备与应用
EP4626866A1 (en) * 2022-11-28 2025-10-08 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
TW202446371A (zh) 2023-04-18 2024-12-01 美商英塞特公司 ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IT202300010182A1 (it) 2023-05-19 2024-11-19 Olon Spa Forma solvata di trilaciclib di-cloridrato.
WO2024246713A1 (en) * 2023-05-29 2024-12-05 Fresenius Kabi Oncology Ltd A process for the preparation of cdk inhibiting pyrrolopyrimidine compounds
IT202300010824A1 (it) * 2023-05-29 2024-11-29 Olon Spa Forma solvata di trilaciclib di-cloridrato.
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025134057A1 (en) 2023-12-20 2025-06-26 Assia Chemical Industries Ltd. Solid state forms of trilaciclib citrate salt
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0552237T3 (da) * 1990-10-09 1993-07-28 Neurogen Corp Visse cycloalkyl- og azacycloalkyl-pyrrolopyrimidiner, en klasse af ligander for GABA-receptorer i hjernen
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
KR100960827B1 (ko) * 2001-12-20 2010-06-08 오에스아이 파마슈티컬스, 인코포레이티드 피롤로피리미딘 Ａ₂ｂ 선택성 길항 화합물, 그의 합성방법 및 용도
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
CA2476822A1 (en) * 2002-02-19 2003-08-28 Pharmacia Italia S.P.A. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CA2526578C (en) * 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CA2543308C (en) 2003-10-23 2012-03-06 F. Hoffman-La Roche Ag Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
GB0327380D0 (en) * 2003-11-25 2003-12-31 Cyclacel Ltd Method
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
JP5498796B2 (ja) * 2006-12-21 2014-05-21 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピラゾロ−キナゾリン誘導体、これらの調製方法及びキナーゼ阻害剤としてのこれらの使用
AU2008268442A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
NZ586069A (en) * 2007-12-19 2012-05-25 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
PE20110419A1 (es) 2008-08-22 2011-07-13 Novartis Ag Compuestos de pirrolo-pirimidina como inhibidores de cdk
CA2738909A1 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
EP2341911A4 (en) 2008-10-01 2012-10-24 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2013148748A1 (en) * 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors

Also Published As

Publication number Publication date
JP6389926B2 (ja) 2018-09-12
JP2016183161A (ja) 2016-10-20
AU2020203037B2 (en) 2021-09-09
HRP20161092T1 (hr) 2016-10-21
DK2632467T3 (en) 2016-08-15
HK1197067A1 (en) 2015-01-02
IL237581B (en) 2018-11-29
EP3381920A1 (en) 2018-10-03
EP3567042B1 (en) 2021-07-07
AU2020203035A1 (en) 2020-05-28
MX367795B (es) 2019-09-06
WO2012061156A1 (en) 2012-05-10
AU2016204879B2 (en) 2018-02-01
EP3118203B1 (en) 2018-10-24
AU2011323739A1 (en) 2013-05-02
CN103429243A (zh) 2013-12-04
CN103429243B (zh) 2016-06-08
MX2020005498A (es) 2021-08-26
MX2013004681A (es) 2013-10-17
KR20180135086A (ko) 2018-12-19
SG189525A1 (en) 2013-05-31
JP2013543845A (ja) 2013-12-09
IL237581A0 (en) 2015-04-30
IL252108A0 (en) 2017-07-31
CY1118004T1 (el) 2017-05-17
HUE030714T2 (en) 2017-05-29
CA2815084A1 (en) 2012-05-10
US20130237544A1 (en) 2013-09-12
EP2955183A1 (en) 2015-12-16
RU2621674C2 (ru) 2017-06-07
RU2013123790A (ru) 2014-12-10
CA2961937A1 (en) 2012-05-10
AU2018202991A1 (en) 2018-05-17
EP3567042A1 (en) 2019-11-13
CN106967074A (zh) 2017-07-21
JP6157680B2 (ja) 2017-07-05
LT2632467T (lt) 2016-09-12
CN103936745B (zh) 2017-04-12
SG10201508715YA (en) 2015-11-27
US8598186B2 (en) 2013-12-03
CN106008533A (zh) 2016-10-12
IL225940A0 (en) 2013-06-27
AU2020203035B2 (en) 2021-09-16
SI2632467T1 (sl) 2016-10-28
CA2815084C (en) 2017-05-09
HK1254345B (en) 2020-04-09
BR112013010018A2 (pt) 2016-08-02
AU2018202991B2 (en) 2020-02-13
EP3118203A1 (en) 2017-01-18
KR20190135556A (ko) 2019-12-06
MX385616B (es) 2025-03-18
PT2632467T (pt) 2016-08-29
MX338327B (es) 2016-04-12
US20130237533A1 (en) 2013-09-12
AU2020203037A1 (en) 2020-05-28
EP2632467A4 (en) 2014-03-26
KR102186969B1 (ko) 2020-12-04
MX379532B (es) 2025-03-10
CN104045654A (zh) 2014-09-17
IL271977A (en) 2020-02-27
US8598197B2 (en) 2013-12-03
CA2961937C (en) 2018-09-25
AU2011323739B2 (en) 2016-05-12
KR102051881B1 (ko) 2019-12-04
PL2632467T3 (pl) 2016-12-30
ES2592515T3 (es) 2016-11-30
KR20140003427A (ko) 2014-01-09
BR112013010018B1 (pt) 2020-11-10
AU2016204879A1 (en) 2016-07-28
EP3381920B1 (en) 2019-03-27
MX2019010602A (es) 2019-10-17
KR20200137048A (ko) 2020-12-08
CN106008533B (zh) 2018-01-23
JP2017186357A (ja) 2017-10-12
EP2632467A1 (en) 2013-09-04
RS55135B1 (sr) 2016-12-30
KR101929593B1 (ko) 2018-12-14
EP2632467B1 (en) 2016-06-22
CN103936745A (zh) 2014-07-23
JP2018193400A (ja) 2018-12-06
IL237582A0 (en) 2015-04-30
JP5923509B2 (ja) 2016-05-24
IL252108B (en) 2020-02-27
EP3981770A1 (en) 2022-04-13
IL271977B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
FR25C1006I2 (fr) Inhibiteurs de pyrazolyl-quinoxaline kinase
SMT201600311B (it) Inibitori di cdk
SMT201500271B (it) Inibitori di neprilisina
SMT201600141B (it) Boronati quali inibitori di arginasi
DK2371923T3 (da) Aflejringshæmmer
BR112013016154A2 (pt) inibidores de faah
DK2710007T3 (da) Kinasehæmmere
SMT201600114B (it) Inibitori di beta-secretasi
CO6970602A2 (es) Inhibidores de quinasa
DK3673906T3 (da) Glycosylceramidsyntase-hæmmere
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
BR112012028556A2 (pt) Indóis
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
DK2466065T3 (da) Brøndkomplettering
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112013025761A2 (pt) inibidores de hsp90
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
BR112013014148A2 (pt) inibidores de corrosão
FR2959228B1 (fr) Nucleotides modifies
DE102010019119B8 (de) Cuttermesser
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
BR112013014484A2 (pt) compostos inibidores de metaloenzimas
DK2652241T3 (da) Brøndkomplettering
BR112013014731A2 (pt) tamavidina modificada